Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Benner

Showing results (321-330 of 347) with videos related to

Pageof 35
Sort By:
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
Leukemia|July 4, 2024
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY studyAlberto Hernández-Sánchez, Teresa González, Marta Sobas, et al.
Leukemia|February 9, 2026
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemiaRabea Mecklenbrauck, Angela Villaverde Ramiro, Eric Sträng, et al.
Cell Reports|July 21, 2021
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancerSebastian M Dieter, Christine Siegl, Paula L Codó, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.
Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.
Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.
Pageof 35

Showing results (321-330 of 347) with videos related to

Sort By:
Pageof 35
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
Leukemia|July 4, 2024
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY studyAlberto Hernández-Sánchez, Teresa González, Marta Sobas, et al.
Leukemia|February 9, 2026
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemiaRabea Mecklenbrauck, Angela Villaverde Ramiro, Eric Sträng, et al.
Cell Reports|July 21, 2021
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancerSebastian M Dieter, Christine Siegl, Paula L Codó, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.
Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.
Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.
Pageof 35